Call Us Now
+91-9891296838

Gazyva (Obinutuzumab)

About Gazyva (Obinutuzumab)

Product: GAZYVA
Molecule Name: obinutuzumab
Manufacturer: Roche
Type: Intravenous infusion
Strength: (25 mg/mL) single-dose vial.
Packing: 1000 mg/40 mL

Gazyva is an anti-cancer chemotherapy drug. Gazyva is classified as a “monoclonal antibody”.Gazyva is given as an infusion into the vein.

South Delhi Pharma can facilitate the supply of “Gazyva (Obinutuzumab)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Gazyva (Obinutuzumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

2,969,883.00

Categories: ,

Get In Touch

Get in touch with us at South Delhi Pharma (SDM), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

8 + 14 =

What GAZYVA is?

GAZYVA (obinutuzumab) is a CD20-directed cytolytic antibody and is indicated:
• in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.
• in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular
lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.

What Obinutuzumab is?

Obinutuzumab is a humanized anti-CD20 monoclonal antibody.It can be used as a first-line treatment for chronic lymphocytic leukemia in combination with chemotherapy or with venetoclax, as a first-line treatment for follicular lymphoma in combination with chemotherapy, and as treatment for relapsed or refractory follicular lymphoma in combination with bendamustine chemotherapy.

Reviews

There are no reviews yet.

Be the first to review “Gazyva (Obinutuzumab)”

Your email address will not be published. Required fields are marked *